Jot Dx ICM

Jot Dx ICM

Clinical Evidence

Clinical Compendium

Insertable Cardiac Monitors (ICMs) are a widely used diagnostic tool to detect arrhythmias. Abbott ICMs with SharpSense™ technology further improve the performance of arrhythmia detection. This compendium is a collection of product and clinical data to help you make informed decisions for your patients.

Insertable Cardiac Monitoring Results in Greater Atrial Fibrillation Diagnosis and Oral Anticoagulation After Cryptogenic Stroke

The featured real-world evidence data comes from a nationwide study of U.S. Medicare beneficiaries diagnosed with cryptogenic stroke. The results demonstrate long-term cardiac monitoring through an ICM device yielded more frequent and timely AF detection rates and oral anticoagulant (OAC) prescriptions compared to short-term external cardiac monitor (ECM) devices. Patients with ICMs were almost 3 times more likely to be diagnosed with AF and to be prescribed an OAC compared to patients who only received an ECM. 

Jot Dx ICM Clinical Case Studies - Key Episodes or All Episodes

ICM expert Dr. Rajdeep Gaitonde shares his experience with Jot Dx ICM, and how he has applied Key Episode technology in his clinical practice to diagnose complex arrhythmias for patients.

Reducing the Electrogram Review Burden Imposed by Insertable Cardiac Monitors


Background: Insertable Cardiac Monitors (ICMs) are essential for ambulatory arrhythmia diagnosis. However, definitive diagnoses still require time‐consuming, manual adjudication of electrograms (EGMs).

Objective: To evaluate the clinical impact of selecting only key EGMs for review. Methods: Retrospective analyses of randomly selected Abbott Confirm Rx™ devices with ≥90 days of remote transmission history were performed, with each EGM adjudicated as true or false positive (TP, FP). For each device, up to 3 “key EGMs” per arrhythmia type per day were prioritized for review based on ventricular rate and episode duration. The reduction in EGMs and TP days (patient‐days with at least one TP EGM), and any diagnostic delay (from the first TP), were calculated versus reviewing all EGMs.

Results: In 1000 ICMs over a median duration of 8.1 months, at least one atrial fibrillation (AF), tachycardia, bradycardia, or pause EGM was transmitted by 424, 343, 190, and 325 devices, respectively, with a total of 95 716 EGMs. Approximately 90% of episodes were contributed by 25% of patients. Key EGM selection reduced EGM review burden by 43%, 66%, 77%, and 50% (55% overall), while reducing TP days by 0.8%, 2.1%, 0.2%, and 0.0%, respectively. Despite reviewing fewer EGMs, 99% of devices with a TP EGM were ultimately diagnosed on the same day versus reviewing all EGMs.

Conclusion: Key EGM selection reduced the EGM review substantially with no delay‐to‐diagnosis in 99% of patients exhibiting true arrhythmias. Implementing these rules in the Abbott patient care network may accelerate clinical workflow without compromising diagnostic timelines. 

Stay up to date with recent news, product highlights and case studies

Manuals & Resources

Cardiovascular Products

Customer Service

MAT-2109519 v3.0